Recombinant Human OTUD7B/Cezanne Catalytic Domain, CF
Recombinant Human OTUD7B/Cezanne Catalytic Domain, CF Summary
Product Specifications
Reaction conditions will need to be optimized for each specific application. We recommend an initial Recombinant Human Cezanne Catalytic Domain concentration of 0.1-1.0 μM.
Asn124 - Leu436
Product Datasheets
Carrier Free
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
E-563
Formulation | 1.8 mg/ml (50 μM) in 50 mM HEPES pH 7.5, 100 mM NaCl, 10 % Glycerol (v/v), 1 mM TCEP |
Shipping | The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended below. |
Stability & Storage: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Reconstitution Calculator
Background: OTUD7B/Cezanne
OTU domain-containing protein 7B (OTUD7B), also known as cellular zinc finger anti-NF-kappa B (Cezanne), is a C64 type peptidase and a member of the ovarian tumor (OTU) protein super-family with a predicted molecular weight of 93 kDa. The human protein shares 90% amino acid sequence identity with its mouse ortholog. Cezanne has been reported to cleave K48-, and K63-linked polyubiquitin chains, but this enzyme displays a very strong preference for K11-linked chains in vitro. It has been shown to play a role in the negative regulation of NF-kappa B signaling, possibly by deubiquitination of RIPK1 and TRAF3. This untagged recombinant protein contains the catalytic domain (including the OTU domain) of Cezanne.
- Bremm, A. et al. (2010) Nat. Struct. Mol. Biol. 17: 939
- Enesa, K. et al. (2008) J. Biol. Chem. 283: 7036
- Evans, P.C. et al. (2003) J. Biol. Chem. 278: 23180
- Hu, H. et al. (2013) Nature 494: 371
Citation for Recombinant Human OTUD7B/Cezanne Catalytic Domain, CF
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
1 Citation: Showing 1 - 1
-
A trio of ubiquitin ligases sequentially drives ubiquitylation and autophagic degradation of dysfunctional yeast proteasomes
Authors: RS Marshall, RD Vierstra
Cell Reports, 2022-03-15;38(11):110535.
Applications: Bioassay
FAQs
No product specific FAQs exist for this product, however you may
View all Proteins and Enzyme FAQsReviews for Recombinant Human OTUD7B/Cezanne Catalytic Domain, CF
There are currently no reviews for this product. Be the first to review Recombinant Human OTUD7B/Cezanne Catalytic Domain, CF and earn rewards!
Have you used Recombinant Human OTUD7B/Cezanne Catalytic Domain, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image